Award honors innovations advancing laboratory science and automation.
HOUSTON, TX, Feb 6, 2025 –Systemic Bio, a 3D Systems company, has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes technological advancements poised to drive innovation in laboratory science and automation. The competition featured cutting-edge developments led by distinguished experts from top institutions worldwide.
The award highlights Systemic Bio’s proprietary h-VIOS platform, designed to accelerate drug discovery and development using bioprinted human tissues. The company’s presentation focused on the application of its platform to evaluate the safety of antibody-drug conjugates (ADCs). The technology enables early identification of safety concerns, capturing risks that historically have only been discovered during clinical trials, even after non-human primate studies failed to flag such issues.
“I couldn’t be prouder of our team for winning this award,” said Taci Pereira, CEO of Systemic Bio. “This recognition is a testament to our relentless focus on demonstrating the scientific and translational value of our platform. We remain committed to expanding our capabilities and accelerating adoption to improve drug discovery and development.”
Operating from Houston, TX, Systemic Bio has the capability to produce thousands of tissue models under an ISO 7 clean room and a quality management system (QMS). These models support the company’s ongoing collaborations with leading pharmaceutical companies to improve preclinical drug testing and reduce late-stage failures.
The SLAS Innovation Award is presented annually at the SLAS International Conference and Exhibition, recognizing the most forward-thinking technological advancements in the field.
For more information, visit systemic.bio.
